Australia's largest medical research organisation, the National Health and Medical Research Council (NHMRC), has advised that puberty blockers are appropriate for the gender-affirming care of young people in certain circumstances. This advice follows a year-long review of international evidence.
The federal government commissioned the NHMRC to develop this advice last year, in response to bans on puberty blockers and hormones in public hospitals in Queensland and the Northern Territory. The New Zealand government later implemented similar bans.
The NHMRC's interim national clinical practice guidelines, released on Monday, recommend conditional use of puberty suppressants for children. The council rejected alternative approaches, such as the "wait and see" model, stating that withholding care "can affect the young person’s physical and mental health, wellbeing, and ability to function."
The guidelines state that gender incongruence is the clinical term for a difference between a person’s gender and their sex recorded at birth, and it is not a mental health disorder. Puberty blockers, which stop the body from producing oestrogen and testosterone, have been used to treat various conditions, including precocious puberty, since the 1970s, and in gender-affirming care since the 1990s.